Dexcom Inc Stock EBITDA

DXCM Stock

USD 74.46 0.78 1.04%

DexCom Inc fundamentals help investors to digest information that contributes to DexCom's financial success or failures. It also enables traders to predict the movement of DexCom Stock. The fundamental analysis module provides a way to measure DexCom's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DexCom stock.

		Last Reported	Projected for Next Year
	EBITDA	916.7 M	962.5 M

As of the 22nd of November 2024, EBITDA is likely to grow to about 962.5 M.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

DexCom Inc Company EBITDA Analysis

DexCom's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current DexCom EBITDA

916.7 M

Most of DexCom's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DexCom Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

DexCom EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for DexCom is extremely important. It helps to project a fair market value of DexCom Stock properly, considering its historical fundamentals such as EBITDA. Since DexCom's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of DexCom's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of DexCom's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Total Current Assets	Retained Earnings	Accounts Payable	Total Liab	Common Stock	Property Plant Equipment	Short Term Investments	Long Term Debt	Net Receivables	Short Term Debt	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Good Will	Capital Surpluse	Treasury Stock	Intangible Assets	Long Term Debt Total	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.95	1.0	0.81	0.92	0.99	0.81	0.98	0.98	0.97	0.97	0.38	0.76	1.0	0.81	0.84	0.88	-0.92	0.87	0.85	0.91	0.86	0.96	0.92	0.8
Total Stockholder Equity	0.98		0.89	0.98	0.73	0.88	0.96	0.72	0.94	0.97	0.93	0.92	0.42	0.65	0.99	0.8	0.87	0.92	-0.93	0.81	0.89	0.89	0.81	0.98	0.94	0.7
Net Debt	0.95	0.89		0.93	0.9	0.87	0.97	0.89	0.96	0.96	0.91	0.97	0.35	0.86	0.94	0.68	0.67	0.74	-0.83	0.89	0.7	0.79	0.81	0.88	0.81	0.89
Total Current Assets	1.0	0.98	0.93		0.76	0.93	0.99	0.77	0.95	0.98	0.98	0.96	0.34	0.73	0.99	0.83	0.86	0.9	-0.92	0.83	0.89	0.93	0.87	0.96	0.94	0.75
Retained Earnings	0.81	0.73	0.9	0.76		0.62	0.84	0.88	0.88	0.79	0.75	0.88	0.32	0.94	0.8	0.42	0.42	0.52	-0.69	0.87	0.44	0.54	0.65	0.74	0.62	0.92
Accounts Payable	0.92	0.88	0.87	0.93	0.62		0.92	0.74	0.88	0.9	0.92	0.9	0.34	0.68	0.89	0.9	0.87	0.86	-0.86	0.79	0.83	0.95	0.88	0.86	0.83	0.71
Total Liab	0.99	0.96	0.97	0.99	0.84	0.92		0.85	0.98	0.97	0.97	0.99	0.36	0.82	0.98	0.8	0.8	0.85	-0.91	0.89	0.82	0.9	0.88	0.94	0.89	0.84
Common Stock	0.81	0.72	0.89	0.77	0.88	0.74	0.85		0.89	0.76	0.75	0.91	0.45	0.91	0.78	0.57	0.54	0.56	-0.71	0.95	0.43	0.63	0.71	0.71	0.55	0.99
Property Plant Equipment	0.98	0.94	0.96	0.95	0.88	0.88	0.98	0.89		0.94	0.92	0.99	0.43	0.84	0.97	0.74	0.77	0.81	-0.9	0.93	0.74	0.82	0.82	0.92	0.83	0.88
Short Term Investments	0.98	0.97	0.96	0.98	0.79	0.9	0.97	0.76	0.94		0.95	0.94	0.35	0.71	0.98	0.76	0.8	0.87	-0.89	0.81	0.86	0.88	0.83	0.96	0.93	0.74
Long Term Debt	0.97	0.93	0.91	0.98	0.75	0.92	0.97	0.75	0.92	0.95		0.94	0.15	0.75	0.96	0.83	0.8	0.85	-0.87	0.76	0.86	0.93	0.9	0.91	0.93	0.73
Net Receivables	0.97	0.92	0.97	0.96	0.88	0.9	0.99	0.91	0.99	0.94	0.94		0.37	0.87	0.96	0.77	0.76	0.8	-0.87	0.92	0.73	0.85	0.86	0.9	0.82	0.9
Short Term Debt	0.38	0.42	0.35	0.34	0.32	0.34	0.36	0.45	0.43	0.35	0.15	0.37		0.24	0.37	0.26	0.43	0.39	-0.46	0.64	0.28	0.29	0.18	0.44	0.17	0.45
Current Deferred Revenue	0.76	0.65	0.86	0.73	0.94	0.68	0.82	0.91	0.84	0.71	0.75	0.87	0.24		0.74	0.52	0.42	0.47	-0.63	0.86	0.38	0.59	0.71	0.64	0.53	0.95
Net Tangible Assets	1.0	0.99	0.94	0.99	0.8	0.89	0.98	0.78	0.97	0.98	0.96	0.96	0.37	0.74		0.79	0.83	0.89	-0.92	0.84	0.86	0.88	0.84	0.97	0.93	0.77
Total Permanent Equity	0.81	0.8	0.68	0.83	0.42	0.9	0.8	0.57	0.74	0.76	0.83	0.77	0.26	0.52	0.79		0.9	0.84	-0.75	0.62	0.82	0.91	0.83	0.75	0.76	0.52
Good Will	0.84	0.87	0.67	0.86	0.42	0.87	0.8	0.54	0.77	0.8	0.8	0.76	0.43	0.42	0.83	0.9		0.97	-0.85	0.65	0.92	0.9	0.84	0.88	0.85	0.48
Capital Surpluse	0.88	0.92	0.74	0.9	0.52	0.86	0.85	0.56	0.81	0.87	0.85	0.8	0.39	0.47	0.89	0.84	0.97		-0.88	0.67	0.96	0.9	0.88	0.94	0.93	0.51
Treasury Stock	-0.92	-0.93	-0.83	-0.92	-0.69	-0.86	-0.91	-0.71	-0.9	-0.89	-0.87	-0.87	-0.46	-0.63	-0.92	-0.75	-0.85	-0.88		-0.81	-0.85	-0.87	-0.79	-0.93	-0.87	-0.68
Intangible Assets	0.87	0.81	0.89	0.83	0.87	0.79	0.89	0.95	0.93	0.81	0.76	0.92	0.64	0.86	0.84	0.62	0.65	0.67	-0.81		0.56	0.7	0.72	0.81	0.62	0.95
Long Term Debt Total	0.85	0.89	0.7	0.89	0.44	0.83	0.82	0.43	0.74	0.86	0.86	0.73	0.28	0.38	0.86	0.82	0.92	0.96	-0.85	0.56		0.92	0.82	0.91	0.95	0.4
Short Long Term Debt	0.91	0.89	0.79	0.93	0.54	0.95	0.9	0.63	0.82	0.88	0.93	0.85	0.29	0.59	0.88	0.91	0.9	0.9	-0.87	0.7	0.92		0.89	0.87	0.89	0.59
Long Term Investments	0.86	0.81	0.81	0.87	0.65	0.88	0.88	0.71	0.82	0.83	0.9	0.86	0.18	0.71	0.84	0.83	0.84	0.88	-0.79	0.72	0.82	0.89		0.85	0.84	0.69
Net Invested Capital	0.96	0.98	0.88	0.96	0.74	0.86	0.94	0.71	0.92	0.96	0.91	0.9	0.44	0.64	0.97	0.75	0.88	0.94	-0.93	0.81	0.91	0.87	0.85		0.95	0.69
Net Working Capital	0.92	0.94	0.81	0.94	0.62	0.83	0.89	0.55	0.83	0.93	0.93	0.82	0.17	0.53	0.93	0.76	0.85	0.93	-0.87	0.62	0.95	0.89	0.84	0.95		0.52
Capital Stock	0.8	0.7	0.89	0.75	0.92	0.71	0.84	0.99	0.88	0.74	0.73	0.9	0.45	0.95	0.77	0.52	0.48	0.51	-0.68	0.95	0.4	0.59	0.69	0.69	0.52

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict DexCom

Ebitda Over Time

DexCom Ebitda

Ebitda

962.53 Million

At this time, DexCom's EBITDA is very stable compared to the past year.

According to the company disclosure, DexCom Inc reported earnings before interest,tax, depreciation and amortization of 916.7 M. This is 4.48% higher than that of the Health Care Equipment & Supplies sector and 42.67% higher than that of the Health Care industry. The ebitda for all United States stocks is 76.49% higher than that of the company.

DexCom EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DexCom's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DexCom could also be used in its relative valuation, which is a method of valuing DexCom by comparing valuation metrics of similar companies.

DexCom is currently under evaluation in ebitda category among its peers.

DexCom ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, DexCom's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to DexCom's managers, analysts, and investors.

Environmental

Governance

Social

DexCom Institutional Holders

Institutional Holdings refers to the ownership stake in DexCom that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of DexCom's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing DexCom's value.

		Shares
Dz Bank Ag Deutsche Zentral-genossenschaftsbank Frankfurt Am Main	2024-06-30	6.7 M
Nuveen Asset Management, Llc	2024-06-30	6.4 M
Ubs Asset Mgmt Americas Inc	2024-09-30	6.3 M
Amvescap Plc.	2024-06-30	6.2 M
Artisan Partners Limited Partnership	2024-06-30	5.6 M
Norges Bank	2024-06-30	5.4 M
Wellington Management Company Llp	2024-06-30	5.3 M
Bank Of New York Mellon Corp	2024-06-30	4.4 M
Blair William & Co	2024-06-30	4.3 M
Vanguard Group Inc	2024-09-30	47.4 M
Blackrock Inc	2024-06-30	34.5 M

DexCom Fundamentals

	Return On Equity	0.32
	Return On Asset	0.0606
	Profit Margin	0.17 %
	Operating Margin	0.15 %
	Current Valuation	29.49 B
	Shares Outstanding	390.6 M
	Shares Owned By Insiders	0.31 %
	Shares Owned By Institutions	96.77 %
	Number Of Shares Shorted	9.36 M
	Price To Earning	245.31 X
	Price To Book	14.85 X
	Price To Sales	7.36 X
	Revenue	3.62 B
	Gross Profit	1.88 B
	EBITDA	916.7 M
	Net Income	541.5 M
	Cash And Equivalents	2.37 B
	Cash Per Share	6.14 X
	Total Debt	2.59 B
	Debt To Equity	1.17 %
	Current Ratio	3.77 X
	Book Value Per Share	5.07 X
	Cash Flow From Operations	748.5 M
	Short Ratio	1.97 X
	Earnings Per Share	1.65 X
	Price To Earnings To Growth	1.18 X
	Target Price	95.31
	Number Of Employees	9.5 K
	Beta	1.17
	Market Capitalization	29.08 B
	Total Asset	6.26 B
	Retained Earnings	1.02 B
	Working Capital	2.87 B
	Current Asset	231.3 M
	Current Liabilities	66.9 M
	Net Asset	6.26 B

About DexCom Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze DexCom Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DexCom using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DexCom Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:

How To Invest In DexCom

Details

Is DexCom Stock a good investment?

Details

What is DexCom's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out DexCom Piotroski F Score and DexCom Altman Z Score analysis.

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.157

Earnings Share

1.65

Revenue Per Share

10.089

Quarterly Revenue Growth

0.02

Return On Assets

0.0606

The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Dexcom Inc Stock EBITDA

DexCom Inc Company EBITDA Analysis

EBITDA

Revenue

-

Basic Expenses

Current DexCom EBITDA

DexCom EBITDA Driver Correlations

DexCom Ebitda

Ebitda

962.53 Million

DexCom EBITDA Peer Comparison

DexCom ESG Sustainability

DexCom Institutional Holders

DexCom Fundamentals

About DexCom Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY